Exploiting the vulnerabilities of drug-resistant cancer for imaging and therapy


October 7, 2024
Cancer Events Virtual Pub

On October 11, 2024, Euro-BioImaging hosts the Cancer Metabolism Series in collaboration with the International Society of Cancer Metabolism (ISCaM). This series of lectures takes place once a month during the Virtual Pub, bringing together speakers from the cancer metabolism field with imaging experts from the Euro-BioImaging network, for exchange with enthusiasts from the biological & biomedical imaging fields in the Virtual Pub audience. Our speaker on October 11 is Tim Witney, King's College London, on " Exploiting the vulnerabilities of drug-resistant cancer for imaging and therapy."

Register

Registration is free and open to all. Please click on the button above to register to attend the Virtual Pub every Friday.

Abstract

Therapy resistance is one of the biggest problems currently facing clinical oncology. Despite a revolution in new anti-cancer therapies, durable responses are often not observed due to acquired or innate resistance to these treatment regimens. Currently, there is no satisfactory way to identify patients who are refractive to therapy early in their treatment pathway. As a result, the majority of cancer deaths result from ineffective treatment of therapy-resistant cancer. The early identification of resistance will enable the clinician to dynamically adapt the patient’s treatment regimen, with the potential to dramatically improve disease outcomes and provide substantial cost savings for the healthcare system. 

Our group is developing a toolbox of molecular imaging agents that bind to biomarkers expressed in therapy-resistant disease. Whilst tumours employ a myriad of different ways to evade death, we have focused our efforts on imaging common downstream pathways that are agnostic to the mechanisms that result in resistance. In this talk, I describe how imaging tumour antioxidant production holds great promise for treatment response monitoring and the prediction of treatment resistance (Fig. 1). I further describe the development of a novel radiotracer for cancer stem cell imaging in refractive disease. We have exploited the overexpression of these cancer-resistance biomarkers to create novel radionuclide and antibody-drug conjugate therapies. Now, we can not only detect treatment failure but will, in the future, be able to provide an effective treatment option for these patients. 

Virtual Pub/Cancer Metabolism Series with Tim Witney

More news from Euro-BioImaging

COMULIS globe logo

February 4, 2025

Congratulations to the successful project in the COMULISglobe international access call

At the end of 2024, Euro-BioImaging ran a successful international user access call within the framework of the COMULISglobe project. Researchers from around…

February 3, 2025

Join us for the Euro-BioImaging Image Data Community Days 2025

Euro-BioImaging is proud to announce that we will be hosting the first Euro-BioImaging Image Data Community Days during the week of 7-11 April 2025.

Ilari Pulli presents WP 6 advancements at the ERIC Forum Annual Meeting.

January 31, 2025

Euro-BioImaging at the ERIC Forum Annual Meeting in Brussels

Euro-BioImaging was excited to take part in the ERIC Forum Annual Meeting and Satellite Industrial event held this week in Brussels. This event brought…